Gemcitabine combined with the monoclonal antibody nimotuzumab is an active first-line regimen in KRAS wildtype patients with locally advanced or metastatic pancreatic cancer: a multicenter, randomized phase IIb study
AbstractBackground. This randomized study was designed to investigate the superiority of gemcitabine (gem) plus nimotuzumab (nimo), an anti-epidermal growth fa
Saved in:
| Main Authors: | , |
|---|---|
| Format: | Article (Journal) |
| Language: | English |
| Published: |
6 July 2017
|
| In: |
Annals of oncology
Year: 2017, Volume: 28, Issue: 10, Pages: 2429-2435 |
| ISSN: | 1569-8041 |
| DOI: | 10.1093/annonc/mdx343 |
| Online Access: | Verlag, Volltext: http://dx.doi.org/10.1093/annonc/mdx343 Verlag, Volltext: https://academic-oup-com.ezproxy.medma.uni-heidelberg.de/annonc/article/28/10/2429/3926574 
|
| Author Notes: | B. Schultheis, D. Reuter, M.P. Ebert, J. Siveke, A. Kerkhoff, W.E. Berdel, R. Hofheinz, D.M. Behringer, W.E. Schmidt, E. Goker, S. De Dosso, M. Kneba, S. Yalcin, F. Overkamp, F. Schlegel, M. Dommach, R. Rohrberg, T. Steinmetz, M. Bulitta, D. Strumberg |
| Summary: | AbstractBackground. This randomized study was designed to investigate the superiority of gemcitabine (gem) plus nimotuzumab (nimo), an anti-epidermal growth fa |
|---|---|
| Item Description: | Gesehen am 27.08.2018 |
| Physical Description: | Online Resource |
| ISSN: | 1569-8041 |
| DOI: | 10.1093/annonc/mdx343 |